RVRyan Verner

Ryan Verner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ryan Verner has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effectiveness and safety of implantable vagus nerve stimulation in people with primary generalized tonic–clonic seizures

    by Katherine Eggleston, Justine Curley, Ryan Verner, Maxine Dibue, Charles Gordon, Gaia Giannicola, Kathryn Nichol

    Objective: Most therapies for drug‐resistant epilepsy (DRE) focus on focal‐onset seizures, the most common seizure types. Studying primary generalized tonic–clonic seizures (PGTCS) is more challenging due to diagnostic and recruitment difficulties. While vagus nerve stimulation (VNS) therapy is globally established in DRE with focal‐onset seizures, approved indications vary by region. This study assesses the safety and effectiveness of VNS therapy in individuals with drug‐resistant PGTCS. Methods: Data from five studies were included in the analysis. The PGTCS group included 170 participants with reported PGTCS who received VNS therapy and completed 24 months of follow‐up. Outcomes included observed and Bayesian‐estimated PGTCS responder rates (≥50% seizure reduction) and seizure frequency changes. Observed rates were determined from clinical studies, while Bayesian responder rates were estimated using a hierarchical model. Results: The Bayesian hierarchical model estimated the 24‐month PGTCS responder rate for patients in CORE‐VNS to be 65.2% (95% credible interval: 55.1%–75.1%). The Bayesian estimate at 24 months for responder rates across all studies was 65.5%. Most responders (91.7%) maintained their response from 6 and 12 months to 24 months. Median seizure frequency decreased by 71.4% for PGTCS and 62.5% for all seizures at 24 months. Treatment‐emergent adverse events (TEAEs) were low and consistent with those seen in people with focal‐onset seizures treated with VNS therapy. No new safety concerns were identified, including no increased risk of Status Epilepticus (SE) or death. Significance: These findings support VNS therapy as a safe and effective treatment for reducing PGTCS in participants with DRE. Plain Language Summary: Primary generalized tonic–clonic seizures (PGTCS) carry higher risks of complications and death than focal‐onset seizures. Vagus nerve stimulation (VNS therapy) is approved for drug‐resistant PGTCS outside the USA. Data from five LivaNova‐sponsored clinical studies show that VNS therapy is safe and effective in adults and children. Among 170 participants, about 66% had a ≥50% reduction in PGTCS at 24 months, and 92% of early responders maintained improvement. Among 149 participants, median PGTCS frequency fell by 71%. Treatment‐emergent adverse events were low, with no new safety concerns identified.


  • Open Access

    CORE-VNS: Dosing and titration of VNS therapy in contemporary clinical practice

    by Ryan Verner, Francesca Beraldi, Michal Tzadok, Firas Fahoum, Riëm El Tahry, Michael A. Gelfand, George Morris, Gholam K. Motamedi, Muhammad Zafar, Arjune Sen, et al.

  • Open Access

    Effect of vagus nerve stimulation therapy on 1-year seizure freedom and quality of life in patients with drug-resistant epilepsy in Japan: plain language summary of a real-world study

    by Naoki Tani, Maxine Dibué, Ryan Verner, Stephany Mai Nishikawa, Charles Gordon, Kensuke Kawai, Fukiko Fujino, Haruhiko Kishima

  • Open Access

    Resting‐state functional connectivity changes with microburst vagus nerve stimulation therapy

    by Jane B Allendorfer, Rodolphe Nenert, Elhum Shamshiri, Giovanni Ranuzzi, Jason Begnaud, Ryan Verner, Jerzy P Szaflarski, Microburst Study Group

    Objective: Microburst vagus nerve stimulation (μVNS) may reduce seizure frequency in drug‐resistant epilepsy (DRE) via targeted thalamic plasticity. We prospectively investigated the role of thalamic resting‐state functional connectivity (rsFC) in μVNS effects and hypothesized a relationship between thalamic rsFC and long‐term seizure frequency changes. Methods: Eighteen patients with focal (Foc) and 10 with generalized (Gen) DRE underwent 3T resting‐state fMRI at 2 weeks post‐implantation and before starting (baseline) and after 6 months of μVNS. Resting‐state fMRI analyses were performed using in‐house Matlab scripts. Nonparametric permutation tests assessed baseline group differences in rsFC between automated anatomical atlas (AAL) brain regions and longitudinal rsFC changes. Spearman correlations were performed between baseline thalamus rsFC and percent change in seizures after 12 months of μVNS (PCHG‐12). Results: Gen had stronger baseline rsFC between AAL regions compared with Foc. Gen showed significant baseline‐to‐6‐month rsFC changes, including a decrease between the left thalamus and left superior parietal lobule. Foc showed significant rsFC changes, including increases between the left thalamus and four regions: right middle cingulum (Lthal‐Rmidcing), right angular gyrus (Lthal‐Rangular), left angular gyrus (Lthal‐Langular), and left precuneus (Lthal‐Lprecuneus), and increases between the right thalamus and left angular gyrus (Rthal‐Langular). Foc showed negative correlations between PCHG‐12 and baseline rsFC for Lthal‐Rmidcing ( ρ = −0.61; p = 0.007), Lthal‐Rangular ( ρ = −0.51; p = 0.032), and Rthal‐Langular ( ρ = −0.52; p = 0.028). Significance: Baseline thalamic rsFC is correlated with long‐term seizure frequency reduction with μVNS in focal DRE. RsFC may be a potential biomarker for μVNS response in focal‐onset seizure patients; this relationship may be different in DRE with generalized seizures. Plain Language Summary: We investigated how stimulating the vagus nerve in a specific manner may reduce seizure frequency in people with drug‐resistant epilepsy through its actions on how a part of the brain called the thalamus is functionally connected to other brain regions. People with focal seizures showed a different pattern of changes in thalamus functional connectivity than those with generalized seizures after 6 months of stimulation. People with focal seizures also showed that stronger functional connectivity between the thalamus and other brain regions at baseline was related to a greater decrease in seizure frequency after 12 months of stimulation.


  • Open Access

    Reduction of generalized tonic–clonic seizures following vagus nerve stimulation therapy: CORE ‐ VNS Study 24‐month follow‐up

    by Ana Suller Marti, Ryan Verner, Mark Keezer, Andrea Andrade, Martin Veilleux, Kenneth Myers, Gaia Giannicola, Kathryn Nichol, Jorge G. Burneo, the CORE‐VNS Registry Group

    Objective: Generalized tonic–clonic seizures (GTCS) are considered to be among the most devastating seizures due to increased health risks. Use of device‐based therapies, such as vagus nerve stimulation (VNS), is common for those resistant to antiseizure medications and important for those in whom resective surgery is not feasible. Our objective is to investigate whether adjunctive VNS can reduce the frequency of GTCS. Methods: Participants were enrolled in an international, multicenter, prospective observational study (CORE‐VNS) on seizure and nonseizure outcomes following the implantation of VNS. Participants with GTCS at baseline were selected for analysis. Baseline seizure frequency data and patient‐reported outcome measures were collected at 3, 6, 12, 24, and 36 months. This interim analysis compared baseline data to VNS therapy outcomes through 24 months. Results: A total of 115 participants met the inclusion criteria. Following 12 months of VNS, participants experienced a median GTCS reduction of 73.9%, with 37% of participants reporting seizure freedom from GTCS for the 3 months prior to the 12‐month follow‐up. This outcome remained stable at 24 months, with a median GTCS reduction of 77% and 42.6% of participants reporting seizure freedom for the 3 months prior to the 24‐month visit. After 12 months of VNS, the number of participants reporting the postictal severity of their most debilitating seizure as “severe” or “very severe” dropped from 52.8% to 25.3% (21/83). After 24 months of VNS, the percentage of participants reporting these levels of postictal severity was 26.3% (20/76). The participants' drug load did not change significantly during the follow‐up. Adverse events were typical of those previously documented in patients with drug‐resistant epilepsy (DRE) using VNS. Significance: Adjunctive VNS therapy was effective in reducing GTCS frequency in study participants. The sustained and consistent nature of the response further supports VNS as a long‐term effective therapy in patients with DRE who have GTCS.


  • Open Access

    Vagus nerve stimulation in Lennox–Gastaut syndrome: Twenty‐four‐month data and experience from the CORE ‐ VNS study

    by Paul Lyons, James Wheless, Ryan Verner, Jose Ferreira, Kore Liow, James Valeriano, Gholam Motamedi, Gaia Giannicola, Kathryn Nichol

    Objective: The drug‐resistant epilepsy associated with Lennox–Gastaut syndrome (LGS) has a long‐term effect on patients and is difficult to treat with conventional pharmacological and nonpharmacological therapies. Our objective is to demonstrate that adjunctive vagus nerve stimulation (VNS) can help manage the seizures associated with LGS. Methods: CORE‐VNS (NCT03529045) is a prospective, multicenter, multinational observational study to collect data on seizure and nonseizure outcomes following treatment with VNS. Participants were identified as having a documented LGS diagnosis and received initial VNS implants. Baseline seizure frequency data and patient‐reported outcome measures were collected at 3, 6, 12, 24, and 36 months. This interim analysis compared baseline data to VNS therapy outcomes at 24 months, and the results are presented here. Results: Sixty participants in the CORE‐VNS study had a diagnosis of LGS and received an initial implant of VNS. The population was geographically diverse: 31.7% European, 26.7% from the Americas, and 26.7% from the Western Pacific. The median age at implant was 11.8 years (range = 2.2–47.6), and only 26.7% of those diagnosed with LGS were >18 years of age. Most (70%) of the participants had severe cognitive impairment. The LGS participants failed a median of 6 antiseizure medications, and 83.3% had not undergone epilepsy surgery. The LGS responder rate (≥50% reduction in seizure frequency) at 24 months for focal and generalized seizures was 66.7% and 47.4%, respectively. Some participants (20%, 12/60) experienced a ≥80% reduction in total seizure frequency. VNS was well tolerated, with only 15% (9/60) reporting at least one treatment‐emergent adverse event, primarily cough, dysphonia, and oropharyngeal pain. Significance: LGS participants who received adjunctive VNS therapy to manage seizures were predominantly severely cognitively impaired children. Reductions in seizure frequency, including those with drops, and the sustained nature of the response support VNS as a promising therapy in LGS.


  • Open Access

    One‐year seizure freedom and quality of life in patients with drug‐resistant epilepsy receiving adjunctive vagus nerve stimulation in Japan

    by Naoki Tani, Maxine Dibué, Ryan Verner, Stephany Mai Nishikawa, Charles Gordon, Kensuke Kawai, Haruhiko Kishima

    Objective: Amount of seizure‐free days is a critical determinant of quality of life (QoL) in patients with drug‐resistant epilepsy (DRE). The fractions of patients experiencing prolonged periods of seizure freedom with adjunctive vagus nerve stimulation (VNS) have yet to be assessed on a large scale.Methods: Retrospective analysis of patients in the Japanese VNS prospective observational registry who experienced at least 1 year of seizure freedom from all seizures, focal seizures, or tonic–clonic seizures (TCS), as well as patient‐reported change in QoL in these groups.Results: The study included 362 patients with DRE, 147 were female (40.6%), and the median age at VNS implant was 23.0 years (range: 1.0–73.0). A total of 225 patients reported focal seizures and 184 patients reported TCS. After 36 months of adjunctive VNS, the cumulative proportion of patients experiencing at least 1 year of complete seizure freedom was 11% (38/356) with an average duration of seizure freedom of 19.4 months. In patients with focal seizures, 25% (n = 57/225) experienced at least 1 year of freedom from focal seizures with an average duration of 24.8 months. Higher cumulative rates of freedom from TCS were observed: 55% (n = 101/184) experienced at least 1 year without TCS with an average duration of TCS‐free periods of 28.9 months. 82.1% of patients with 12‐month complete seizure freedom reported markedly improved or improved QoL compared with 51.9% of patients who were not seizure‐free. QoL changes in patients with 12‐month seizure freedom from TCS and focal seizures were similar: 61.8% and 63% of respective patients reported either markedly improved or improved QoL at 36 months.Significance: Complete seizure freedom is rare in patients treated with VNS; however, this analysis found approximately half of patients who experienced TCS prior to VNS experienced prolonged periods of freedom from TCS with adjunctive VNS.Plain Language Summary: We studied patients in Japan with epilepsy that is difficult to treat. To understand if adding vagus nerve stimulation (VNS) helps such patients, we looked at which patients stopped having all seizures or stopped having a specific seizure type (such as tonic–clonic seizures or focal seizures), and how long these periods lasted. With VNS treatment, about 2 out of 4 patients with tonic–clonic seizures and 1 out of 4 patients with focal seizures had more time without these seizure types. Without seizures, patients felt better about their daily lives. Even patients who still had seizures felt better about their daily lives after 3 years of VNS treatment.Trial Registration: The clinical trial registry number is UMIN000014728.


  • Open Access

    Feasibility study of microburst VNS therapy in drug-resistant focal and generalized epilepsy

    by Cornelia Drees, Pegah Afra, Ryan Verner, Lesley Kaye, Amy Keith, Mei Jiang, Jerzy P. Szaflarski, Kathryn Nichol, Danielle McDermott, Mesha Gay Brown, et al.


  • Open Access

    Assumptions and statistical inference

    by Kathryn Nichol, Ryan Verner, Charles Gordon, Danielle Urry, LivaNova Clinical and Medical Affairs

  • Open Access

    ASCEND: A randomized controlled trial of titration strategies for vagus nerve stimulation in drug-resistant epilepsy

    by Anto I. Bagić, Ryan Verner, Pegah Afra, Selim Benbadis, Anto Bagić, Selim Benbadis, George Nune, Toufic Fakhoury, Sandy Helmers, Daniel Winkel, et al.